Begum Aydogan Mathyk

University of South Florida
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Fertility preservation remains a significant concern for individuals undergoing gonadotoxic treatments. While traditional fertility preservation techniques are well-established, these methods can be time-consuming and limited by various medical or logistical barriers. In recent years, the potential of mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) has emerged as a promising, paradigm-shifting approach in fertility preservation. Preclinical studies have demonstrated the protective and regenerative properties of EVs in chemotherapy-induced ovarian and testicular damage in animal models. EVs provide a cell-free therapy that can potentially preserve ovarian function in females and spermatogenesis in males without the need for surgery or delay in cancer treatment. Additionally, using MSC-derived EVs offers advantages over traditional stem cell therapies, such as a reduced risk of immune rejection, targeted treatment, and avoidance of safety concerns associated with stem cell-based therapies. Future directions include enhancing the therapeutic potential of MSC-derived EVs through genetic engineering or cell priming techniques to target specific tissues and further optimize their utilization in fertility preservation. Given the potential of MSC-derived EVs to protect fertility in both females and males, this approach could revolutionize treatment in oncofertility. Further research, including clinical trials, is necessary to confirm the safety and efficacy of MSC-derived EVs, focusing on premature ovarian insufficiency. Looking ahead, MSC-derived EVs could revolutionize fertility preservation, offering hope for cancer patients and individuals exposed to various environmental risks affecting reproduction, including in space exploration, where protection from cosmic radiation is essential.

Year:

2026

Importance and objective: Voice changes during menopause affect patients’ communication and quality of life. This narrative review aims to provide a comprehensive exploration of voice changes during menopause. It presents objective and subjective/symptomatic changes as well as treatment options for this population. Lastly, it identifies areas of research and future directions needed to serve this population through collaboration between voice experts and gynecologists. Methods: To inform this narrative review, a literature review was conducted using the PubMed database, encompassing publications from January 2005 to January 2025. The review synthesized research on hormonal influences, acoustic analyses, laryngeal imaging, and patient-reported outcomes, with a focus on understanding the physiological mechanisms underlying menopausal voice alterations. Results: The review reveals a complex narrative of vocal transformation during menopause. Hormonal decline—characterized by reduced estrogen and progesterone levels—precipitates significant laryngeal changes. Up to 46% of menopausal women experience perceptible vocal modifications, including decreased fundamental frequency (by 0.94 semitones), increased vocal instability, and reduced phonation capabilities. Particularly vulnerable are professional voice users, who face unique challenges in maintaining vocal performance. Hormone therapy demonstrates potential protective effects, though findings remain inconsistent. Discussion and conclusion: Menopause-related voice disorders represent a nuanced and underexplored medical phenomenon. This review underscores the critical need for interdisciplinary research that integrates gynecology, otolaryngology, endocrinology, and speech pathology. Future investigations could focus on developing AI-driven voice biomarkers, conducting longitudinal studies, and creating targeted interventions that recognize the voice and respiratory transitions women experience during menopause.

Year:

2026

Year:

2026

The development of paper-based systems has revolutionized point-of-care (POC) applications by enabling rapid, robust, accurate and sensitive biochemical analysis, infectious disease diagnosis, and fertility monitoring.

Year:

2025

Human engagement in extreme activities, from spaceflight to deep-sea diving and extreme sports, presents unique physiological challenges. Understanding the molecular mechanisms underlying adaptations to these demands is crucial for developing strategies to enhance human performance and resilience in such environments. This review integrates multi-omics data across a range of extreme phenotypes, including astronauts, scuba divers, acute alcohol consumers, long-haul flight passengers, bodybuilders, and simulation racers. We analyze current literature in genomic, transcriptomic, proteomic, metabolomic, and metagenomic studies to identify common and phenotype-specific adaptations, highlighting potential biomarkers and pathways associated with resilience in harsh conditions. This integrated approach offers insights into human adaptability and provides a foundation for developing personalized strategies to mitigate risks and enhance performance in extreme environments, with particular relevance to extended spaceflight.

Year:

2025

BACKGROUND: Imaging plays a critical role in evaluating gynecologic emergencies. However, access to such technology is limited in austere environments such as spaceflight. Portable point-of-care ultrasonography (POCUS) offers rapid diagnostic capabilities potentially useful for supporting women's health. However, the feasibility of using portable POCUS for gynecological imaging in spaceflights characterized by shifts in weightlessness has not been previously evaluated. INSTRUMENT: Transabdominal ultrasonography was undertaken to assess the feasibility of using portable POCUS for gynecologic scans during a parabolic flight. EXPERIENCE: Despite rapidly alternating gravitational changes and the close proximity of other crew members, a participant successfully obtained clear diagnostic images of the uterus and measured three-dimensional bladder volumes during a parabolic flight aboard a Falcon 20 aircraft without privacy concerns. During the hypergravity phase (approximately 2 G) of the flight, heavier upper-extremity movement and probe positioning created challenges to successful imaging. However, minimizing head movement helped to stabilize the vestibular system during gravity changes, successfully mitigating symptoms such as vertigo, nausea, and dizziness. This strategy facilitated smoother transitions between gravitational forces and enabled the participant to obtain uterine imaging during the microgravity phase of the flight. CONCLUSION: The use of a handheld portable POCUS device is feasible during parabolic flight, establishing an important precedent useful for supporting women's health in space. Future technology needs to incorporate training models, augmented reality, and advanced artificial intelligence–based tools to direct self-scanning capabilities for participants who do not have medical experience.

Year:

2025

The introduction of poly (ADP-ribose) polymerase inhibitors (PARPi) into the management of ovarian cancer has transformed the treatment landscape for patients affected by this malignancy. However, as the use of PARPi expands into both frontline maintenance and recurrence settings, the emergence of drug resistance has become a significant clinical challenge in the treatment of these patients. Although platinum-based chemotherapy (PBC) and PARPi act through different mechanisms—PBC causes DNA damage while PARPi blocks its repair—both depend on the integrity of DNA damage repair (DDR) pathways, leading to overlapping mechanisms of resistance. Here, we review the key resistance mechanisms shared by PARPi and PBC, and then we discuss their clinical implications in the management of patients with ovarian cancer. We also examine clinical rationale supporting the hypothesis that prior PARPi exposure may reduce the efficacy of subsequent PBC in patients experiencing a disease recurrence. Furthermore, we review preliminary clinical data assessing the potential role of PARPi retreatment in patients who have previously progressed on PARPis.

Year:

2025

Collaborators (6)

JangKeun Kim

Senior Research Associate

Weill Cornell Medicine

UNITED STATES
View details

Ayman Al-Hendy

Professor

University of Chicago

UNITED STATES
View details

Jiwoon Park

Weill Cornell Medicine

UNITED STATES
View details

Savas Tasoglu

Max Planck Institute for Intelligent Systems

GERMANY
View details

Rupal Patel

Professor

Northeastern University

UNITED STATES
View details

Cihan Halicigil

Assistant Professor

Yale University

UNITED STATES
View details